# A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Source: https://onco.cc/trials/nct02970318/  
OnCo record `nct02970318` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib, Rituximab, Idelalisib and Bendamustine in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL is a phase 3 interventional study registered as NCT02970318 by Acerta Pharma BV, with 310 participants enrolled, started 2017-02-02 and due to reach its primary completion in 2021-09-03. Interventions recorded: Acalabrutinib (ACP-196), Rituximab, Idelalisib and Bendamustine. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02970318
- Phase: 3
- Setting: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
- Sponsor: Acerta Pharma BV
- Enrolled: 310
- Outcomes: Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment: Arm A: Acalabrutinib Monotherapy vs Arm B: Investigators Choice 16.5 months, HR 0.31; IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis: Arm A: Acalabrutinib Monotherapy 126 participants vs Arm B: Investigator's Choice 117 participants

## Sources

- ClinicalTrials.gov NCT02970318: https://clinicaltrials.gov/study/NCT02970318

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Idelalisib](https://onco.cc/drugs/idelalisib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02970318.json